A Simple Prognostic Score for Critical COVID-19 Derived from Patients without Comorbidities Performs Well in Unselected Patients.
COVID-19
comorbidities
critical disease
prognosis
vaccination
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
25 Mar 2022
25 Mar 2022
Historique:
received:
01
02
2022
revised:
18
03
2022
accepted:
23
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
We aimed to search for laboratory predictors of critical COVID-19 in consecutive adults admitted in an academic center between 16 September 2020−20 December 2021. Patients were uniformly treated with low-molecular-weight heparin, and dexamethasone plus remdesivir when SpO2 < 94%. Among consecutive unvaccinated patients without underlying medical conditions (n = 241, 49 year-old median, 71% males), 22 (9.1%) developed critical disease and 2 died (0.8%). White-blood-cell counts, neutrophils, neutrophil-to-lymphocyte ratio, CRP, fibrinogen, ferritin, LDH and γ-GT at admission were each univariably associated with critical disease. ROC-defined cutoffs revealed that CRP > 61.8 mg/L, fibrinogen > 616.5 mg/dL and LDH > 380.5 U/L were each associated with critical disease development, independently of age, sex and days from symptom-onset. A score combining higher-than-cutoff CRP (0/2), LDH (0/1) and fibrinogen (0/1) predicted critical disease (AUC: 0.873, 95% CI: 0.820−0.926). This score performed well in an unselected patient cohort (n = 1228, 100% unvaccinated) predominantly infected by the alpha variant (AUC: 0.718, 95% CI: 0.683−0.753), as well as in a mixed cohort (n = 527, 65% unvaccinated) predominantly infected by the delta variant (AUC: 0.708, 95% CI: 0.656−0.760). Therefore, we propose that a combination of standard biomarkers of acute inflammatory response, cell death and hypercoagulability reflects the severity of COVID-19 per se independently of comorbidities, age and sex, being of value for risk stratification in unselected patients.
Identifiants
pubmed: 35407418
pii: jcm11071810
doi: 10.3390/jcm11071810
pmc: PMC8999885
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Blood. 2021 May 20;137(20):2838-2847
pubmed: 33824972
Monaldi Arch Chest Dis. 2022 Feb 22;:
pubmed: 35225441
BMJ Open Respir Res. 2020 Dec;7(1):
pubmed: 33293361
Clin Microbiol Infect. 2022 Feb;28(2):273-278
pubmed: 34600119
N Engl J Med. 2022 Jan 13;386(2):105-115
pubmed: 34942066
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Int J Infect Dis. 2021 Oct;111:108-116
pubmed: 34416403
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Arterioscler Thromb Vasc Biol. 2020 Nov;40(11):2764-2775
pubmed: 32907371
BMJ. 2020 Sep 9;370:m3339
pubmed: 32907855
N Engl J Med. 2021 Oct 7;385(15):1355-1371
pubmed: 34496194
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Lancet Respir Med. 2021 Apr;9(4):349-359
pubmed: 33444539
Lancet Microbe. 2022 Jan;3(1):e4-e5
pubmed: 34901896
Wien Klin Wochenschr. 2021 Sep;133(17-18):875-881
pubmed: 34081191
J Cachexia Sarcopenia Muscle. 2022 Mar 7;:
pubmed: 35257497
Aging (Albany NY). 2020 Jul 13;12(13):12493-12503
pubmed: 32658868
Ann Epidemiol. 2021 May;57:14-21
pubmed: 33662494
Chest. 1992 Jun;101(6):1644-55
pubmed: 1303622
J Infect Public Health. 2022 Jan;15(1):13-20
pubmed: 34861603
Nat Commun. 2020 Dec 9;11(1):6317
pubmed: 33298944
J Gen Intern Med. 2021 May;36(5):1338-1345
pubmed: 33575909
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620
pubmed: 34617959
Epidemiol Infect. 2020 Oct 14;148:e255
pubmed: 33050972
J Transl Med. 2020 Dec 7;18(1):461
pubmed: 33287826